Contributions
Abstract: EP1416
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Inflammation and tissue damage
Objective: To assess the effects of treatment with interferon beta 1 a on oxidative stress state and to correlate with neuro degeneration biomarkers in normal appearing white matter.
Methods: 31 patients (9 man and 22 women) with RRMS and a Kurtzke Expanded Disability Scale Score (EDSS) of 0-5.5 were recruited in 4 MS Clinics and included in a prospective, longitudinal study of Intra muscular Interferon (IM IFN) beta-1a in RRMS. All patients were followed up for a period of 2 years. Every three months disability was assessed. Measure of the oxidation state and H-MRS were performed at baseline, 12 and 24 months. At the beginning of the study MRI and H-MRS were also performed on 10 healthy, age matched control subjects with not known systemic or neurological disease.
RESULTS: It was seen a trend by which decreasing the oxidative environment, thanks to medication, produced an increase of NAA and a decrease of mI in the second year; on the other hand when the drug failed to control the oxidative environment occurred a NAA decreased and a increased mI. Furthermore, it was found a relationship between the change in NAA in the first 24 months after treatment and changes in sulfhydryl groups in the first 12 months following the introduction of treatment (r = - 0.8, p = 0.02). Loss of choline after two years of treatment was related to loss of sulfhydryl groups in the first 12 months following the introduction of treatment (r = - 0.9, p = 0.001).
Conclusions: The oxidative stress immediately following the introduction of immuno-modulating medication can play an important role in the disability developed during the evolution of the disease: The treatment decreases the oxidative stress in the early stages of the disease and this will reduce both energy damage and axonal damage and with the surplus energy would be delayed the remyelination and gliosis
Disclosure: nothing to disclose
Abstract: EP1416
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Inflammation and tissue damage
Objective: To assess the effects of treatment with interferon beta 1 a on oxidative stress state and to correlate with neuro degeneration biomarkers in normal appearing white matter.
Methods: 31 patients (9 man and 22 women) with RRMS and a Kurtzke Expanded Disability Scale Score (EDSS) of 0-5.5 were recruited in 4 MS Clinics and included in a prospective, longitudinal study of Intra muscular Interferon (IM IFN) beta-1a in RRMS. All patients were followed up for a period of 2 years. Every three months disability was assessed. Measure of the oxidation state and H-MRS were performed at baseline, 12 and 24 months. At the beginning of the study MRI and H-MRS were also performed on 10 healthy, age matched control subjects with not known systemic or neurological disease.
RESULTS: It was seen a trend by which decreasing the oxidative environment, thanks to medication, produced an increase of NAA and a decrease of mI in the second year; on the other hand when the drug failed to control the oxidative environment occurred a NAA decreased and a increased mI. Furthermore, it was found a relationship between the change in NAA in the first 24 months after treatment and changes in sulfhydryl groups in the first 12 months following the introduction of treatment (r = - 0.8, p = 0.02). Loss of choline after two years of treatment was related to loss of sulfhydryl groups in the first 12 months following the introduction of treatment (r = - 0.9, p = 0.001).
Conclusions: The oxidative stress immediately following the introduction of immuno-modulating medication can play an important role in the disability developed during the evolution of the disease: The treatment decreases the oxidative stress in the early stages of the disease and this will reduce both energy damage and axonal damage and with the surplus energy would be delayed the remyelination and gliosis
Disclosure: nothing to disclose